School of Public Affairs, Zhejiang University, Hangzhou, China.
Department of Global Health, Peking University School of Public Health, Beijing, China.
JMIR Public Health Surveill. 2022 Jun 7;8(6):e33484. doi: 10.2196/33484.
COVID-19 vaccines are in short supply worldwide. China was among the first countries to pledge supplies of the COVID-19 vaccine as a global public product, and to date, the country has provided more than 600 million vaccines to more than 200 countries and regions with low COVID-19 vaccination rates. Understanding the public's attitude in China toward the global distribution of COVID-19 vaccines could inform global and national decisions, policies, and debates.
The aim of this study was to determine the attitudes of adults living in China regarding the global allocation of COVID-19 vaccines developed in China and how these attitudes vary across provinces and by sociodemographic characteristics.
We conducted a cross-sectional online survey among adults registered with the survey company KuRunData. The survey asked participants 31 questions about their attitudes regarding the global allocation of COVID-19 vaccines developed in China. We disaggregated responses by province and sociodemographic characteristics. All analyses used survey sampling weights.
A total of 10,000 participants completed the questionnaire. Participants generally favored providing COVID-19 vaccines to foreign countries before fulfilling domestic needs (75.6%, 95% CI 74.6%-76.5%). Women (3778/4921, 76.8%; odds ratio 1.18, 95% CI 1.07-1.32; P=.002) and those living in rural areas (3123/4065, 76.8%; odds ratio 1.13, 95% CI 1.01-1.27; P=.03) were especially likely to hold this opinion. Most respondents preferred providing financial support through international platforms rather than directly offering support to individual countries (72.1%, 95% CI 71%-73.1%), while for vaccine products they preferred direct provision to relevant countries instead of via a delivery platform such as COVAX (77.3%, 95% CI 76.3%-78.2%).
Among our survey sample, we found that adults are generally supportive of the international distribution of COVID-19 vaccines, which may encourage policy makers to support and implement the distribution of COVID-19 vaccines developed in China worldwide. Conducting similar surveys in other countries could help align policy makers' actions on COVID-19 vaccine distribution with the preferences of their constituencies.
全球范围内，新冠疫苗供应短缺。中国是最早承诺将新冠疫苗作为全球公共产品供应的国家之一，截至目前，中国已向 200 多个低疫苗接种率国家和地区提供了超过 6 亿剂疫苗。了解中国公众对全球新冠疫苗分配的态度，可以为全球和国家决策、政策和辩论提供信息。
本研究旨在确定中国成年人对中国开发的新冠疫苗在全球分配的态度，以及这些态度如何因省份和社会人口特征而有所不同。
我们对 KuRunData 调查公司注册的成年人进行了一项横断面在线调查。该调查询问了参与者 31 个关于他们对中国开发的新冠疫苗在全球分配的态度的问题。我们根据省份和社会人口特征对回答进行了分类。所有分析均使用调查抽样权重。
共有 10000 名参与者完成了问卷。参与者普遍赞成在满足国内需求之前向外国提供新冠疫苗（75.6%，95%置信区间 74.6%-76.5%）。女性（4921 人中有 3778 人，76.8%；优势比 1.18，95%置信区间 1.07-1.32；P=.002）和农村地区居民（4065 人中有 3123 人，76.8%；优势比 1.13，95%置信区间 1.01-1.27；P=.03）尤其如此。大多数受访者更愿意通过国际平台提供财政支持，而不是直接向个别国家提供支持（72.1%，95%置信区间 71%-73.1%），而对于疫苗产品，他们更愿意直接提供给相关国家，而不是通过 COVAX 等交付平台（77.3%，95%置信区间 76.3%-78.2%）。
在我们的调查样本中，我们发现成年人普遍支持新冠疫苗的国际分配，这可能鼓励政策制定者支持并实施在中国开发的新冠疫苗在全球范围内的分配。在其他国家进行类似的调查可以帮助使政策制定者在新冠疫苗分配方面的行动与选民的偏好保持一致。
